“GLP-1 weight-loss drugs cause muscle loss.”
Moderate confidence because trials and reviews consistently show some lean-mass loss during substantial GLP-1-associated weight loss, but lean mass includes more than skeletal muscle. Fat loss is usually greater, and available functional measures do not show a consistent decline in strength. Individual risk changes with age, frailty, nutrition, activity and the amount of weight lost.
GLP-1-associated weight loss can include a reduction in lean mass, but lean mass is not the same as skeletal muscle. Most weight lost is fat, and current studies do not show a consistent loss of strength or physical function. Whether the change represents harmful muscle loss depends on the person and clinical context.
Safety note: Do not stop a prescribed medicine because of a body-composition headline. Older or frail adults and people with low muscle reserve, poor intake or weakness may need closer nutrition and function monitoring.
Talk to a healthcare professional if: Discuss weakness, falls, difficulty eating, rapid weight loss or concern about muscle reserve with your prescriber. Ask whether strength or function testing and an individualized nutrition and activity plan are appropriate.
Some lean tissue may be lost as body weight falls, but a scan result alone does not show harmful muscle loss. Strength, function, diet, activity and baseline muscle reserve help determine whether the change is clinically important.
Ask your care team how they will monitor weight-loss pace, nutrition, strength and function, especially if you are older, frail or losing weight rapidly.